Collagen-induced arthritis in the diabetes-resistant BB (DR BB)/Wor rat is a severe, aggressive disease initiated by immunization with heterologous native Type II collagen. Onset of clinical symptoms reproducibly occurs in 100% of animals between days 10 and 12 following collagen immunization. Hypertrophy of the synovial lining is the first histological manifestation of the early inflammatory arthritis. A mild inflammatory infiltrate in the synovium rapidly becomes a fibrovascular pannus eroding articular cartilage and subchondral bone. Beginning at the joint margins, an active synovitis is present. Light microscopy and immunohistochemical staining show the infiltrate to be comprised of mononuclear (lymphocytes, macrophages) and polymorphonuclear inflammatory cells. In addition, there is histological evidence for chronic inflammatory nodules and necrotizing vasculitis in connective tissue from diseased joints, both morphologic features associated with rheumatoid arthritis in humans. Subchondral bone erosion appears to be mediated largely by the resorptive action of activated osteoclasts. These histological parameters of disease progression in the DR BB/Wor rat are similar to human rheumatoid arthritis. The extensive degree of similarity in the pathology of DR BB/Wor rat collagen-induced arthritis and human rheumatoid arthritis supports the role of this model as an in vivo disease model for human rheumatoid arthritis.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic, destructive inflammatory disease of human diarthrodial joints. This autoimmune disease is characterized by a chronic proliferative synovitis, and is associated with both humoral and cellular immune responses (5, 6, 22) . Extraarticular manifestations, such as necrotizing vasculitis and rheumatoid nodules, are frequently associated with the disease. Over time, inflammatory-mediated reactions erode both cartilage and subchondral bone. Although the etiology of RA is unknown, susceptibility to disease is associated with inheritance of certain allelic forms of major histocompatibility complex (MHC) Class II genes (4, 8) .
Animal disease models that reproduce the pathology of human RA are of great interest, both as templates for the further dissection of the biology of the human disease and as vehicles for the testing of potential therapeutics designed for treatment. In most models, arthritis develops after exposure of the animals to an inducing agent. Arthritis can be induced in susceptible strains of mice, rats, or nonhuman primates by immunization with heterologous native Type II collagen (CII) (2, 3, 18) , mycobac-teria-containing adjuvant [complete Freund's adjuvant CFA)] (14, 17) , or mycobacterial cell wall fragments suspended in mineral oil (14) . These disease models share certain features with human RA, including clinical appearance of the arthritis, aspects of the histopathology including development of a proliferative synovitis, and MHC-linked genetic susceptibility (2, 3, 14, 17, 18) . However, a detailed histological characterization of disease progression over time in these models has not been reported.
Collagen-induced arthritis (CIA) is induced in rodents by intradermal immunization once or several times with purified native heterologous CII extracted from articular cartilage. The ensuing arthritis generally develops in 40-80% of immunized animals after a 2-3-wk latency period, and both hind-and forelimbs can be affected (9, 15) .
The diabetes-resistant (DR) BB/Wor rat is a subline of the diabetes-prone BB rat, which is susceptible to the development of a severe, aggressive polyarthritis after a single immunization with heterologous CII (19) . Arthritis in the DR BB/Wor rat differs from other rodent collageninduced arthritis models in both its high incidence and short latency after a single exposure to immunizing antigen : Bilateral arthritis develops in the hindpaws with 100% incidence, and clinical signs of disease initially appear 10-12 days after collagen immunization (19) . The unusual severity and penetrance of the arthritis in DR BB/Wor rats has been attributed to the sharing of the genetic element that predisposes humans to the development of RA. This conserved peptide epitope is present on susceptibility-associated human MHC Class II DR alleles and on the DR BB/Wor rat DR-like RT1.D MHC Class II molecule (16, 19) . IgG2a antibodies directed against the immunizing heterologous CII have been shown to be present in arthritic DR BB/Wor rats immunized with human CII, suggesting that humoral mechanisms may play a role in disease pathogenesis in this strain (19) .
We have studied CIA development and progression in DR BB/Wor rats and present a complete characterization of the histopathology of disease from onset to end-stage joint destruction. Morphological features within diseased joints that are also seen in joints from patients with rheumatoid arthritis are presented. Our data support the use of this model as a reasonable animal model of human RA.
MATERIALS AND METHODS
Animals. DR BB/Wor rats were purchased from the University of Massachusetts (Worcester, MA) breeding colony or bred in the G. D. Searle Research Animal Facility (St. Louis, MO) and were housed and cared for in accordance with the guidelines of the Institutional Animal Care and Use Committee and in accordance with National Institutes of Health guidelines on laboratory animal welfare. Equal numbers of males and females, aged 45-65 days (approx. 150 g) were used in these studies.
DR BBlWor Immunization with Bovine CII. Native bovine type II collagen (BIIC) was supplied by Dr. Marie Griffiths, (University of Utah, Salt Lake City) (10) . Except where noted, rats were injected intradermally at the base of the tail with 100 ~Lg BIIC emulsified in IFA (Difco Laboratories Inc., Detroit, MI). The emulsion was made by homogenizing I part native BIIC (4 mg/ml in 0.1 M acetic acid) into 1 part IFA overnight at 4°C. Clinical Scoring of Arthritis in BIIC-Immunized DR BBlWor Rats. Clinical severity of arthritis in the rat paws was scored on a subjective scale ranging from 1 to 4 for each paw: 1 = redness, 2 = swelling, 3 = digit deformity, and 4 = ankle deformity (ankylosis). All clinical score (CS) measurements were performed independently by 2 individuals, without knowledge of the rats' clinical score history. Full ankylosis is scored clinically by lack of motion of the extremity in question. An animal can have a CS of 16 if all paws are fully ankylosed.
Histology. Hindpaws were taken from sacrificed animals at the end of the study, skinned, and placed in 10% buffered phosphate formalin (Fisher Scientific, Pittsburgh, PA) for at least 1 wk before being subjected to acid decalcification (16) . Decalcified paws were embedded in paraffin (13), longitudinally sectioned through the center of the tibia-tarsal joint, and stained with hematoxylin and eosin or Masson trichrome (Histo Techniques, Powell, OH).
Immunohistochemistry. DR BB/Wor hindpaws were removed, immediately frozen on dry ice, and longitudinally sectioned down the midline using a cold hand-held razor saw. Samples were placed in OCT (Baxter, McGraw Park, IL), cut surface up, and then transferred quickly back to dry ice. Bone was removed from the samples using a dissecting microscope and a hand-held rotary tool equipped with fine carbide bits. Samples were periodically covered with dry ice to prevent thawing caused by grinding friction. All of the bone was removed from each sample, leaving soft tissue, including synovial lining. Bone spaces were filled with OCT and 6-uJvt sections obtained using standard cryosectioning techniques.
CD2-expressing cells were identified in prepared sections using a murine IgG2a monoclonal antibody, OX-34, which reacts with the CD2 adhesion molecule on T lymphocytes, natural killer (NK) cells, and tissue macrophages. RT1.D-expressing cells were identified using an RT1.D-specific murine IgGl 1 monoclonal antibody, OX-17 (Pharmingen, San Diego, CA). Tissue sections were fixed overnight in 0.5% phosphate-buffered formalin. Primary antibodies were placed on sections at 1 pLg/ml for 1 h at 37°C. Primary antibodies were detected using an alkaline phosphatase kit (AK5001, Vector Laboratories, Burlingame, CA) using the recommended procedure. The AP substrate was developed using a Vector RED kit (SK5100, Vector Laboratories) and counterstained with contrast blue.
RESULTS

Responsiveness of Clinical Disease Progression to Dose of CII
The arthritis that develops in DR BB/Wor rats after a single intradermal immunization with heterologous CII shows a rapid clinical progression (Fig. lA ). Animals show clinical signs of disease beginning 10-12 days after immunization with BIIC in IFA; these initial signs are restricted to redness in 1 or both hindpaws. These early clinical signs of disease rapidly progress to bilateral hindpaw ankylosis in 100% of immunized rats by days [16] [17] [18] [19] . Figure 1 B compares the gross appearance of a normal DR BB/Wor rat hindpaw and a fully ankylosed hindpaw from a BIIC-immunized DR BB/Wor rat at day 21. Incidence of forepaw involvement in immunized animals is somewhat lower and more variable than the hindpaw disease, affecting 20-100% of rats, and generally after day 20 (Fig. 1A ). By contrast, rats injected with IFA alone do not develop clinical signs of arthritic disease (data not shown).
The effect of BIIC dose on arthritis progression in the DR BB/Wor rat (Fig. lA ) has been studied. A single intradermal injection of 100 pLg BIIC is sufficient to induce aggressive disease; a single injection of 200 jjbg BIIC induces disease with the same kinetics. Also, injected single doses up to 400 jig show the same kinetics of disease development (data not shown). Injection of a single 50-pLg dose of BIIC did not induce clinical disease in these animals (Fig. lA) , nor did this low dose induce any histological changes to the hindpaw joints (data not shown). However, immunization with multiple doses of 25 or 50pLg BIIC on days 1, 3, and 7 can induce severe clinical arthritis in DR BB/Wor rats with 100% incidence, with clinical disease onset at day 10, 3 days after the third dose (data not shown).
Histological Disease Progression in the DR BB Rat Figure 2 shows a microscopic analysis of disease progression in BIIC-immunized DR BB/Wor rats. Figure 2A shows a light micrograph of an hematoxylin and eosin (H&E)-stained tibia-tarsal joint section from a normal unimmunized DR BB/Wor rat. The first histological signs of disease in BIIC-immunized rats appears at day 10, when hypertrophy of the synovial lining is observed (Fig. 2B ). The section shown in Fig. 2B comes from a paw with a clinical score of 0. At day 10, mild mononuclear cell infiltration of the synovium is visible. There is no cellular infiltrate before day 10. With disease progression, the synovial tissue becomes hypercellular and well vascularized, so that by day 13 the extremity has a CS of 3. At this stage, the synovial lining has been replaced by an inflammatory granulation tissue, or pannus, which is already eroding the articular cartilage beginning at the joint margins (transition zone) where the articular cartilage ends and the joint capsule attaches to the bone (Fig. 2C ). The early synovial infiltrate is comprised largely of mononuclear cells, macrophages, and lymphocytes, as well as large numbers of polymorphonuclear cells (Fig. 2D ). By day 21 (CS = 4), this infiltrating pannus has significantly eroded the articular cartilage and subchondral bone, both from the joint margins and the periarticular space ( Fig. 2E ). By day 34 (CS = 4), the pannus and the inflammatory reaction have eroded the total articular surface and obliterated the joint space, resulting in complete fibrous ankylosis (Fig.   2F ). We see no evidence of inflammatory foci arising in bone rather than synovium. CD2 is a cell-surface adhesion protein present on T lymphocytes, NK cells, and tissue macrophages. Staining of synovium for this protein confirms the influx of these cells into the synovium between days 11 and 13 (Fig.  3A, B) , concomitant with the influx of inflammatory cells (Fig. 2) . Given the association of the conserved MHC Class II epitope with RA development in humans, and the sharing of this epitope with the DR BB/Wor rat RTl.D molecule, it was important to determine whether RT1.D-positive cells were present in the synovium of arthritic DR BB/Wor rats. Immunohistochemical staining with an RT1.D-specific monoclonal antibody showed that RT1.D-positive mononuclear cells infiltrate the synovium in large numbers concommitant with the initial influx of inflammatory cells, between days 11 and 13 (Fig. 3C, D) .
Additional Histopathologic Similarities
Between DR BB-CIA and Human RA Detailed histological evaluation of the arthritic disease in the DR BB/Wor rat reveals several morphological and histopathological features common to human RA. Nearly all arthritic DR BB/Wor rats show evidence of vascular edema and necrosis of vessels within the synovium (Fig.  4A ). The vessels first show signs of subendothelial edema, beginning about day 11. Mononuclear cells penetrate the vessel wall, and vacuoles are visible in the outer vessel wall; the vessel becomes hemorrhagic and finally necrotic. This histological progression resembles necrotizing vasculitis seen in human RA (7) . The rheumatoid nodule, a radially arranged aggregate of mononuclear cells containing a central area of necrosis, is the most characteristic histopathologic lesion of human RA, found in 25% of RA patients (11, 21) . We have found chronic inflammatory nodules in the synovial connective tissue of arthritic DR BB/Wor rats, between days 19 and 75 following BIIC immunization (Fig. 4B,  day 19 ). These nodule-like structures have a defined morphology, consisting of a central zone comprised of necrotic tissue and polymorphonuclear cells, surrounded by a layer of radially oriented mononuclear cells. Multinucleated giant cells are present in the outer hypercellular zone and are features of a granulomatous nodule (Fig.   4B ).
As in human RA, destruction of subchondral bone in DR BB/Wor-CIA appears to be mediated by the erosive action of osteoclasts. These multinucleated giant cells are seen in sections from arthritic animals in close association with scalloped areas of resorbed bone (Fig. 4C ).
DISCUSSION
CIA in rodents is a chronic, peripheral autoimmune arthritis that shares certain phenotypic, histologic, and immunologic features with human rheumatoid arthritis and is widely used as a model of human RA. Susceptibility to disease is controlled by multiple genes, both MHC-and non-MHC-linked (1, 9, 20) . Arthritis is induced by immunization with purified native heterologous CII and shows variability among immunized strains in both incidence and severity (9) . DR BB/Wor rats develop an unusually aggressive arthritis following immunization with a single dose of heterologous CII (19) . Both cellular and humoral mechanisms appear to be important in the development of CIA in this strain (12, 19) .
The early changes in the synovium and articular cartilage in DR BB/Wor-CIA resemble those seen in RA joints but on a much accelerated temporal scale. Hypertrophy of the synovial lining and increased cellularity and vascularity of the synovial connective tissue are seen in both DR BB/Wor-CIA and human RA. An erosive pannus comprised of fibrovascular connective tissue and mononuclear and polymorphonuclear inflammatory cells infiltrates the articular cartilage and subchondral bone beginning at the joint margins.
Localization of necrotizing vasculitis and rheumatoidlike nodules to the synovium further liken disease in this model to human RA (7, 21) . The same progressive degeneration of the vessel wall is seen in advanced human rheumatoid vasculitis. Acute necrotizing vasculitis can affect large or small arteries in some RA patients with high titers of rheumatoid factor and is thought to be caused by antigen-antibody complex formation and deposition (7) . Significantly, arthritis in the DR BB/Wor rat is associated with high antibody titers to the immunizing antigen (12, 19) . In RA, both vasculitis and rheumatoid nodule formation are predominantly extraarticular disease manifestations, whereas in arthritic DR BB/Wor rats, these pathologies are noted within the synovial connective tissue. It is of interest, and a distinguishing feature of CIA in the DR BB/Wor rat, that rheumatoid nodule formation has not been reported in any other animal model of RA.
It has been suggested that cartilage erosion in this model occurs bidirectionally, originating both from within the synovium and from within the subchondral compartment (19) . We see no evidence for this in our histo- logical analysis. Instead, the histological evidence presented here suggests that erosion of bone in DR BB/Wor-CIA is mediated through the direct resorptive activity of osteoclasts and indirectly by proteases exuded by PMNs. Osteoclasts are visible at the pannus-bone junction and neutrophils are present in the pannus infiltrating bone in joints from arthritic DR BB/Wor rats. Osteoclasts are important in the degradation of bone in RA (11) . Activation of osteoclast bone remodeling function in RA and CIA may represent a cellular response to injury. While osteoclast activation is responsible for the bulk of subchondral bone destruction in RA and CIA, proteolytic enzymes, including collagenases, produced by the pannus are also thought to play a role in the destruction of bone (11) .
The influx of RTl.D+ cells into the synovial connective tissue as part of the earliest cellular response to CII immunization suggests that they may play a role as antigen-presenting cells in the initiation and maintenance of this immune-mediated disease. It has been suggested that the autoimmune response associated with rheumatoid arthritis may be initiated and maintained by the presentation of arthritogenic peptide fragments by MHC Class II molecules encoding the conserved &dquo;RA-associated&dquo; epitope (4, 8) . The sharing of this human RA-associated peptide epitope with the DR BB/Wor rat RT1.D Class II molecule and the susceptibility of DR BB/Wor rats to unusually aggressive CIA suggest that this epitope on the RTl.D molecule may play a pathogenic role in disease in DR BB/Wor rats, perhaps by allowing presentation of particular CII peptide fragments to trigger activation of pathogenic collagen-specific T cells. In this regard, it is interesting that soluble CTLA-4, which blocks T-cell function, prevents arthritis development on this model (12) .
Analysis of the histopathology of CIA in the DR BB/Wor rat shows the progression of arthritic disease in this strain to resemble human RA. These histomorphologic similarities, as well as the increased incidence and rapid onset of disease in the DR BB/Wor rat, support use of this disease model as appropriate for the testing of potential therapeutics for the treatment of RA. The current treatments for RA are largely unsatisfactory. The available therapies alleviate pain associated with inflammation but do not affect disease progression. The identification of an animal disease model that mimics so closely the pathologies associated with RA invites detailed analysis of the anti-rheumatic effects of agents like methotrexate and gold, which are used for the treatment of RA and will also allow testing and identification of novel disease-modifying therapeutic agents for the treatment of RA.
